Pelthos Therapeutics (PTHS)
:PTHS
Top Page
Pelthos Therapeutics
(PTHS)
Select Model
Select Model
Rating:52Neutral
Price Target:
$24.50
▲(6.99% Upside)
Action:ReiteratedDate:03/24/26
The score is held back mainly by weak current financials (large losses and ongoing cash burn) and a bearish technical backdrop (trading below major moving averages with negative MACD). Partially offsetting these risks, the latest earnings call points to strong early product traction and a clear path objective toward cash-flow breakeven, though execution and net-pricing (GTN) remain key uncertainties.
Positive Factors
Commercial Traction
ZELSUVMI's launch produced meaningful, repeatable commercial demand with thousands of dispensed units and strong prescriber uptake. This early product-market fit and growing prescriber base provide a durable revenue foundation that can scale as the company expands its salesforce and distribution.
Negative Factors
Cash Burn
Sustained negative operating and free cash flow creates dependence on external funding. Ongoing cash burn constrains strategic flexibility, risks covenant or refinancing issues, and forces financing choices that can dilute equity or increase leverage unless the company materially narrows losses or achieves breakeven.
Read all positive and negative factors
Positive Factors
Negative Factors
Commercial Traction
ZELSUVMI's launch produced meaningful, repeatable commercial demand with thousands of dispensed units and strong prescriber uptake. This early product-market fit and growing prescriber base provide a durable revenue foundation that can scale as the company expands its salesforce and distribution.
Read all positive factors
Pelthos Therapeutics (PTHS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$76.84M
Dividend YieldN/A
Average Volume (3M)30.94K
Price to Earnings (P/E)―
Beta (1Y)1.92
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees4
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding3,355,543
10 Day Avg. Volume22,109
30 Day Avg. Volume30,941
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.50
Price to Sales (P/S)3.47
P/FCF Ratio-2.57
Enterprise Value/Market Cap0.41
Enterprise Value/Revenue1.87
Enterprise Value/Gross Profit2.99
Enterprise Value/Ebitda-1.05
Forecast
1Y Price Target
$57.14Price Target Upside149.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Pelthos Therapeutics Business Overview & Revenue Model
Company Description
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children ...
How the Company Makes Money
null...
Pelthos Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
34
Negative
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 16.80M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 10.52M | 0.00 | 0.00 | 0.00 | -209.05K |
| EBITDA | -30.07M | -7.17M | -6.86M | -2.32M | 0.00 |
| Net Income | -43.32M | -7.96M | -7.38M | -2.46M | -595.39K |
Balance Sheet | |||||
| Total Assets | 130.40M | 1.37M | 96.39K | 55.07K | 0.00 |
| Cash, Cash Equivalents and Short-Term Investments | 18.02M | 513.44K | 96.39K | 55.07K | 0.00 |
| Total Debt | 34.83M | 2.19M | 1.27M | 540.43K | 1.10M |
| Total Liabilities | 91.52M | 4.08M | 6.54M | 3.76M | 3.68M |
| Stockholders Equity | 38.88M | -2.71M | -6.44M | -3.71M | -3.68M |
Cash Flow | |||||
| Free Cash Flow | -22.69M | -5.79M | -981.03K | -1.57M | -1.59M |
| Operating Cash Flow | -22.59M | -5.79M | -981.03K | -1.57M | -1.59M |
| Investing Cash Flow | -5.24M | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 45.34M | 6.21M | 1.02M | 1.62M | 1.59M |
Pelthos Therapeutics Risk Analysis
Pelthos Therapeutics disclosed 69 risk factors in its most recent earnings report. Pelthos Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Pelthos Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $76.84M | -1.35 | ― | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $74.39M | -3.10 | 15.86% | ― | -0.32% | 94.05% | |
47 Neutral | $155.25M | -8.55 | -1197.81% | ― | ― | 30.16% | |
47 Neutral | $99.98M | -4.95 | 252.30% | ― | 234.73% | 81.16% | |
43 Neutral | $57.92M | -2.28 | -55.88% | ― | ― | 1.40% | |
43 Neutral | $24.19M | -2.09 | 389.21% | ― | ― | -234.46% |
* Healthcare Sector Average
PTHS
Pelthos Therapeutics
22.90
9.40
69.63%
IMUX
Immunic
1.19
0.31
34.62%
FBIO
Fortress Biotech
2.31
0.90
63.83%
VRCA
Verrica Pharmaceuticals
5.82
1.39
31.50%
TIL
Instil Bio
8.54
-5.64
-39.77%
TVGN
Tevogen Bio Holdings
5.81
-44.19
-88.38%
Pelthos Therapeutics Corporate Events
Business Operations and StrategyFinancial DisclosuresM&A TransactionsPrivate Placements and FinancingProduct-Related Announcements
Pelthos Highlights 2025 Results and Portfolio Expansion Progress
Positive
Mar 19, 2026
On March 19, 2026, Pelthos Therapeutics reported fourth-quarter and full-year 2025 results, highlighting the July 2025 launch of ZELSUVMI, which generated $16.2 million in net sales through year-end and drove a 28% sequential revenue increase to $...
Business Operations and StrategyPrivate Placements and Financing
Pelthos Therapeutics Secures $50 Million Venture Loan Financing
Positive
Jan 13, 2026
On January 12, 2026, Pelthos Therapeutics and its subsidiaries entered into a senior secured venture loan and security agreement with Horizon Technology Finance for a term loan facility of up to $50 million, of which $30 million was funded at clos...
Business Operations and StrategyExecutive/Board Changes
Pelthos Therapeutics Details Q1 2026 Growth Strategy
Positive
Jan 12, 2026
On January 6, 2026, Pelthos Therapeutics’ board, acting on its compensation committee’s annual review, approved revisions to cash and equity compensation for non-employee directors effective January 1, 2026, increasing the annual cash ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.